From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – BREAST CANCER
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in breast cancer
Dr Luca Arecco, a medical oncologist at the University of Genova (Italy) and the Institut Jules Bordet (Belgium), presents four trials from the oral abstract session on the adjuvant early
Dr Laure-Anne Teuwen, a medical oncologist at the University Hospital of Antwerp in Belgium, reports on four presentations from the 2024 ASCO conference’s rapid oral session on metastatic breast cancer.<br
Prof Dr François Duhoux, a medical oncologist at the Cliniques Universitaires Saint-Luc (Belgium), discusses the most remarkable presentations on metastatic breast cancer from ASCO 2024.
The first trial is
Dr Elisa Agostinetto, a medical oncologist and research fellow at Institut Jules Bordet in Brussels, Belgium, provides a comprehensive overview of five selected abstracts presented at ASCO 2024 during the
In-depth stories about breast cancer
Dr Paolo Tarantino and Dr Elisa Agostinetto discuss the results of a real-world study of trastuzumab deruxtecan in metastatic breast cancer.
Trastuzumab deruxtecan is significantly changing breast cancer treatment,
In the mini-oral abstract session, Prof Federico Rojo presented the results of the CIBOMA-GEICAM trial, which assessed the benefit of capecitabine in early-stage triple-negative breast cancer following standard neoadjuvant chemotherapy.
This study analysed data from the DESTINY-Breast 01, 02, and 03 trials, focusing on outcomes according to patients’ responses to therapy with T-DXd in HER2+ metastatic breast cancer. DESTINY-Breast 01
The study aimed to evaluate clinical trials focusing on older cancer patients, recognising their underrepresentation despite accounting for 40% of the cancer population. A systematic review was conducted, analysing data
This study presented at ASCO 2024 by Dr Luca Arecco in the oral abstract session focused on early-stage breast cancer among young patients carrying BRCA1 or BRCA2 pathogenic variants, as
Dr Nicholas Mai presents real-world data on sequential ADC treatment.
This study examined the sequential treatment of breast cancer using two antibody-drug conjugates, Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan
Prof Dr Laurence Buisseret and Dr Elisa Agostinetto, medical oncologists at the Institut Jules Bordet in Brussels, Belgium, discuss the updated results of the DESTINY-Breast 03 study.
Prof Dr Giuseppe Curigliano, a medical oncologist at the European Institute of Oncology and University of Milan, Italy, presented the long-awaited results of the DESTINY-Breast 06 trial at ASCO 2024
Dr Elisa Agostinetto and Prof Dr Laurence Buisseret, both medical oncologists at the Institut Jules Bordet in Brussels, Belgium, discuss the exciting findings on antibody-drug conjugate (ADC) drugs in breast
Breast cancer poster selection
The data presented here is from a pre-planned analysis of the Flipper trial, which compares fulvestrant plus palbociclib versus fulvestrant alone. This analysis employs a highly sensitive method to detect
This study explores the role of ctDNA in low estrogen receptor (ER) tumours, particularly luminal breast cancer. The research started with the premise that not all luminal breast cancers are
In this study, researchers focused on cyclin-E1 amplified breast cancer, found in approximately 3-7% of cases. This subset exhibited distinct clinical, pathological, and genomic characteristics.
Patients with cyclin-E1 amplification
Dr Frederic Forget discusses in this poster AIPAC-003, a new study with eftilagimod Alpha (efti).
The poster discusses AIPAC, a new compound acting as a LAG-3 agonist that aims